Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

NCT07091279

Status	RECRUITING
Phase	Phase 2
Sponsor	Jeremy Veenstra-vanderweele
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (11)

- Age between 12-40 years.
- Clinical best-estimate diagnosis of autism spectrum disorder
- Occurrence of severe challenging behaviors, such as aggression, self-injury, and/or severely disruptive or destructive behavior, leading to safety concerns or serious impact of the quality of life, at least weekly over the past 2 months before screening.
- Score in the ASD range on the Autism Diagnostic Observation Schedule conducted at the time of study entry or in the past 5 years
- Clinical Global Impression Severity scale (CGI-S) score of 4 or above at Baseline

... and 6 more (see full listing online)

Exclusion (18)

- Those who are unable to provide informed consent and have no parent/guardian/legally authorized representative to provide informed consent for study enrollment
- Change in psychotropic medication or behavioral intervention (except when caused by vocational, habilitation, or school schedule) within two months before randomization.
- Asthma or history of any disorder involving bronchoconstriction in the past 5 years.
- Cardiovascular history in which the use of propranolol at high doses would be contraindicated, as determined by consulting cardiologist (such as AV block, sick sinus syndrome, valvular pathologies, cardiomyopathies, or vascular disease).
- Uncontrolled seizure disorder (a seizure within the past year and/or changes in seizure medication in the previous six months).

... and 13 more (see full listing online)

Locations (2 total)

New York State Institute for Basic Research (IBR), Staten Island, New York, United States
Center for Autism and the Developing Brain, White Plains, New York, United States